Cadrenal TherapeuticsCVKD
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 9 institutions reported holding Cadrenal Therapeutics Inc. (CVKD) in their 13F filings, down 1 from Q1 2024. 2 opened new positions and 3 sold out. The largest holders were Avantax Planning Partners, Inc. ($53K), Geode Capital Management, LLC ($29K) and Renaissance Technologies ($28K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Cadrenal Therapeutics Inc.
- CUSIP
- 127636108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $7K |
| Exits | 3 | $835K |
All 13F filers, Q1 2024 → Q2 2024: 119,774 shares bought and 1,466,973 shares sold, net −1,347,199 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Avantax Planning Partners, Inc. | 0.00% | Add +300.3% | 113,305 | $53K |
| Geode Capital Management, LLC | 0.00% | Add +43.6% | 61,554 | $29K |
| Renaissance Technologies | 0.00% | Reduce -59.8% | 59,491 | $28K |
| Citadel Advisors | 0.00% | Reduce -2.3% | 54,543 | $26K |
| Virtu Financial LLC | 0.00% | Reduce -23.6% | 24,737 | $12K |
| Two Sigma Securities, LLC | 0.00% | New | 15,858 | $7K |
| Biltmore Family Office, LLC | 0.00% | No change | 11,000 | $5K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +1.5% | 9,666 | $5K |
| Bank of America Corp. | 0.00% | New | 81 | $38 |
"% of holder's portfolio" is CVKD's weight in each manager's 13F, not the share of Cadrenal Therapeutics Inc. the manager owns.